In this issue, explore antisense oligonucleotides, including:

• An overview of recent advances with hybridization-based assays to quantify antisense oligonucleotides in support of pharmacokinetic or toxicokinetic preclinical and clinical studies;

• Regulatory and bioanalytical considerations for these studies;

• Two case studies illustrating Altasciences’ capabilities and knowledge in the field.

Click here to download a PDF, readable version of Issue 12: https://www.altasciences.com/sites/default/files/2020-11/The%20Altascientist_issue12_oligonucleotides.pdf

CHAPTERS:

- 0:35 — Section 1: Introduction

- 1:05 — Section 2: Recent Advances in Antisense Oligonucleotide Research

- 3:00 — Section 3: Regulatory Considerations

- 4:49 — Section 4: Bioanalytical Considerations

- 10:04 — Section 5: Case Study 1 — Resolving Issues with Matrix Effect

- 12:48 — Section 6: Case Study 2 — Stability of Antisense Oligonucleotide in Tissue Matrix

- 14:52 — Section 7: Conclusion

About Altasciences:

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.